Eli Lilly's Chief Financial Officer (CFO), Anat Ashkenazi, receives a compensation package that includes a base salary of $1 million, alongside a significant sign-on equity grant and an opportunity for additional bonuses.
Eli Lilly CFO Compensation Breakdown
Anat Ashkenazi's compensation package as Eli Lilly's CFO is structured to reflect her executive role and experience. The known components of her compensation are detailed below:
- Base Salary: Ashkenazi is set to receive an annual base salary of $1 million. This fixed component forms the core of her remuneration.
- Sign-on Equity Grant: As part of her compensation arrangements, she also received a $13.1 million sign-on equity grant. This grant was comprised of restricted stock, and the reference indicates it was tied to her prior role as Alphabet's CFO, often common practice to compensate for forfeited equity or to attract top talent.
- Bonus Opportunity: In addition to her base salary, Ashkenazi has an opportunity to earn bonuses, although the specific amount or structure of these bonuses is not publicly detailed in the provided information.
This structure is typical for high-ranking corporate executives, blending fixed salary with performance-based incentives and long-term equity to align interests with shareholder value.
Compensation at a Glance
For clarity, here's a summary of the known compensation components for Eli Lilly's CFO:
Compensation Component | Amount | Details |
---|---|---|
Base Salary | $1,000,000 | Annual fixed compensation. |
Sign-on Equity Grant | $13,100,000 | Comprised of restricted stock, as Alphabet's CFO. |
Bonus Opportunity | Unspecified | Additional performance-based compensation. |
For more information on executive compensation in the pharmaceutical industry, you can refer to reports on CFO compensation trends.